Vaxart, Inc.
Biotechnology ResearchCalifornia, United States51-200 Employees
Vaxart, Inc. is a mid-sized biotechnology company focused on developing oral vaccines delivered as pills. Its approach targets mucosal surfaces—the mouth, nose, and gut—to stimulate IgA and T-cell responses at the sites where pathogens enter the body. Headquartered in South San Francisco, California, the company operates in the biotechnology research sector as a clinical-stage developer of oral vaccine pills designed to replace or supplement injections. It has advanced its programs to Phase II trials for an oral COVID-19 vaccine and an oral Norovirus vaccine, and it is the only company to reach Phase II for a COVID-19 vaccine pill. Beyond COVID-19 and norovirus, Vaxart is pursuing vaccines for other pathogens, including influenza, and a therapeutic vaccine for HPV, reflecting a broader focus on oral vaccines across infectious diseases and therapeutic indications. A notable development in 2026 was the appointment of James Breitmeyer to the Board of Directors.
1-888-653-2347 
support@leadiq.com 
